Veronesi U et al. (2006) Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17: 1065–1071
A 15-year follow-up study by Veronesi et al. has demonstrated that the synthetic retinoid fenretinide can reduce the risk of second breast cancer by 50% in premenopausal women aged 40 years or younger with early-stage breast cancer.
The researchers analyzed data from a subgroup of 1,739 women enrolled in a phase III trial of fenretinide efficacy and who continued long-term follow-up at the Istituto Nazionale Tumori in Milan, Italy. Women with a diagnosis of stage I primary breast cancer who had received first-line therapy were randomized to undergo either observation or treatment with fenretinide 200 mg daily for 5 years. Incidence of both contralateral and ipsilateral second breast cancers was recorded. After a median follow-up of 14.6 years, the rate of second breast cancers in the fenretinide group was 17% lower than in the observation group. When the data were stratified by menopausal status, however, premenopausal women receiving fenretinide had a significantly lower risk of developing second breast cancer than postmenopausal women (hazard ratio 0.62; 95% CI 0.46–0.83). Hazard curves indicated that fenretinide reduces risk by 51% and 48% in women aged 35 years or younger and 40 years or younger, respectively. This protective effect lasted for up to 15 years; that is, up to 10 years after completion of fenretinide therapy.
The authors conclude that these data provide the rationale for a trial of fenretinide chemoprevention in healthy premenopausal women at high risk of breast cancer, such as those with BRCA1 or BRCA2 mutations.
Rights and permissions
About this article
Cite this article
Fenretinide can halve the risk of second breast cancer in premenopausal women. Nat Rev Clin Oncol 3, 408 (2006). https://doi.org/10.1038/ncponc0541
Issue Date:
DOI: https://doi.org/10.1038/ncponc0541